Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, phase 3 LUX-Lung 8 (LL8) trial of afatinib (A) versus erlotinib (E) for the second-line treatment of advanced squamous cell carcinoma (SCC) of the lung.

Second Line ◽

Open Label ◽

Phase 3 ◽

Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung

Annals of Oncology ◽

10.1093/annonc/mdw383.38 ◽

2016 ◽

Vol 27 ◽

pp. vi428 ◽

Cited By ~ 2

Author(s):

G. Goss ◽

K.H. Lee ◽

E. Felip ◽

M. Cobo ◽

K. Syrigos ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Line Treatment ◽

Second Line ◽

Open Label ◽

Phase 3 ◽

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00006-6 ◽

2015 ◽

Vol 16 (8) ◽

pp. 897-907 ◽

Cited By ~ 233

Author(s):

Jean-Charles Soria ◽

Enriqueta Felip ◽

Manuel Cobo ◽

Shun Lu ◽

Konstantinos Syrigos ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Line Treatment ◽

Second Line ◽

Open Label ◽

Phase 3 ◽

Randomised Controlled

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)70124-5 ◽

2015 ◽

Vol 16 (5) ◽

pp. 583-594 ◽

Cited By ~ 239

Author(s):

Jean-Pascal H Machiels ◽

Robert I Haddad ◽

Jérôme Fayette ◽

Lisa F Licitra ◽

Makoto Tahara ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

Second Line ◽

Open Label ◽

Phase 3 ◽

Metastatic Squamous Cell Carcinoma ◽

Head Neck

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial

EClinicalMedicine ◽

10.1016/j.eclinm.2021.100940 ◽

2021 ◽

Vol 37 ◽

pp. 100940

Author(s):

Glenwood D Goss ◽

Manuel Cobo ◽

Shun Lu ◽

Konstantinos Syrigos ◽

Ki Hyeong Lee ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Final Analysis ◽

Line Treatment ◽

Second Line ◽

Phase 3

Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(21)00378-2 ◽

2022 ◽

Author(s):

Xiangrui Meng ◽

Tao Wu ◽

Yonggui Hong ◽

Qingxia Fan ◽

Zhonghai Ren ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Line Treatment ◽

Second Line ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(20)30110-8 ◽

2020 ◽

Vol 21 (6) ◽

pp. 832-842 ◽

Cited By ~ 12

Author(s):

Jing Huang ◽

Jianming Xu ◽

Yun Chen ◽

Wu Zhuang ◽

Yiping Zhang ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Second Line ◽

Open Label ◽

Second Line Therapy ◽

Phase 3 ◽

Line Therapy ◽

Faculty Opinions recommendation of Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736682352.793578124 ◽

2020 ◽

Author(s):

Jaffer Ajani

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Open Label ◽

Phase 3 ◽

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30626-6 ◽

2019 ◽

Vol 20 (11) ◽

pp. 1506-1517 ◽

Cited By ~ 90

Author(s):

Ken Kato ◽

Byoung Chul Cho ◽

Masanobu Takahashi ◽

Morihito Okada ◽

Chen-Yuan Lin ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Open Label ◽

Phase 3 ◽

Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial

10.1183/13993003.congress-2015.oa265 ◽

2015 ◽

Author(s):

Shirish Gadgeel ◽

Jean-Charles Soria ◽

Enriqueta Felip ◽

Manuel Cobo ◽

Shun Lu ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Phase Iii Trial

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

The Lancet ◽

10.1016/s0140-6736(18)31999-8 ◽

2019 ◽

Vol 393 (10167) ◽

pp. 156-167 ◽

Cited By ~ 315

Author(s):

Ezra E W Cohen ◽

Denis Soulières ◽

Christophe Le Tourneau ◽

José Dinis ◽

Lisa Licitra ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Open Label ◽

Phase 3 ◽